Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market

Jul 03, 2020

10 likes | 20 Views

The total cases of Programmed Death-Ligand 1 (PD-L1) mutated Non-small Cell Lung Cancer (NSCLC) in the 7MM were observed to be 242,014 in 2017. The therapeutic market size of Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) in seven major markets was found to be USD 6,536 million in 2017 which is expected to increase during the study period (2017u20132030). Increasing use of biomarker testing, increase in the mutation specific trials activity, increasing incidence of Programmed Death Ligand 1 (PD-L1) mutated NSCLC are some of the key factors expected to drive the PD-L1 NSCLC Market in the upcoming years. The key players in the PD-L1 NSCLC Market include Pfizer/Merck, Regeneron Pharmaceuticals, Novartis, GlaxoSmithKline and others. For more detailed information on PD-L1 NSCLC Market, visit: https://www.delveinsight.com/report-store/programmed-death-ligand-1-pd-l1-non-small-cell-lung-cancer-nsclc-market

DelveInsight

Download Presentation

Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D